Massive study reveals COVID-19's toll on work and wages
NCT ID NCT07072793
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at over 131,000 high-risk COVID-19 patients in the US to understand how the illness affected their ability to work and the associated costs. Researchers compared those who took the antiviral Paxlovid with those who did not, using insurance claims data from 2021-2022. The goal was to measure missed work days, disability claims, and related expenses, providing insights for employers and public health planning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nirmatrelvir-ritonavir (Paxlovid)
What this could lead to
If successful, this study could help employers and policymakers understand the economic impact of COVID-19 and the value of antiviral treatments in reducing work loss.
What could go wrong
This is an observational study using insurance claims data, so it cannot prove cause and effect. Results may not apply to all populations or reflect real-world work loss accurately.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 (CORONAVIRUS DISEASE 2019) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer New York
New York, New York, 10001, United States